Pharma Jobs

NEW RELEASES :- Pharmatimes

Jemperli accepted for priority review by US FDA August 31, 2026
sBLA covers dMMR/MSI‑H stage II–III rectal cancer
John Pinching
Carterra supports AI‑designed protein study with HT-SPR platforms August 31, 2026
Anthropic, twist and Adaptyv validate 1,320 binders across 15 targets
John Pinching
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer August 27, 2026
Designation supports rapid development of pan‑RAS molecular glue
John Pinching
Avulux gains FDA authorisation for migraine light‑sensitivity lens August 27, 2026
New device classification created for precision optical filter
John Pinching
Leqembi Iqlik launches in US for early Alzheimer’s August 26, 2026
Autoinjector offers at‑home dosing from start of treatment
John Pinching
Lundbeck gains EU orphan status for anti‑ACTH antibody August 26, 2026
European ruling supports development in rare endocrine disorders
John Pinching
AC Immune reports positive phase 1 data for ACI‑19764 August 25, 2026
Early results show safety, CSF penetration and PK clarity
John Pinching
VarmX begins global phase 3 trial for VMX C001 August 25, 2026
First participant enrolled in EquilibriX S study
John Pinching
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough August 25, 2026
Study shows reversible switch for targeted cytokine delivery
John Pinching
MHRA sets out position on microbiome‑based medicinal products August 24, 2026
Agency clarifies UK pathway for emerging therapies
John Pinching

NEW RELEASES :- Pharma Voice

Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales? August 31, 2026
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
Alexandra Pecci
Advances in risk assessment shift the calculus of early intervention trials for MASLD August 31, 2026
How risk prediction is making early intervention trials in MASLD more feasible.
Jolanta M. Wichary, MD, Vice President, Therapeutic Area Lead, Gastroenterology and Hepatology and Jack Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON
New data could widen use of AstraZeneca, Amgen immune disease drug August 28, 2026
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
Delilah Alvarado
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act. August 28, 2026
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
Meagan Parrish
Pharma’s new CEOs to watch August 27, 2026
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
Kelly Bilodeau
3 takeover targets in immunology August 26, 2026
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
Kelly Bilodeau
Is AI finally proving its worth in drug R&D? August 26, 2026
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
Kelly Bilodeau
Legend’s interim CEO sees a shorter path to the next era of CAR-T August 25, 2026
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
Sy Mukherjee
3 potential blockbusters beyond obesity to watch August 24, 2026
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside.
Alexandra Pecci
Tyra’s one-drug, three-indication bet nears its first phase 2 test August 21, 2026
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
Alexandra Pecci

[wp-rss-aggregator feeds="pharmexec-com"]

[wp-rss-aggregator feeds="pharmiweb-com-articles"]

Jemperli accepted for priority review by US FDA
sBLA covers dMMR/MSI‑H stage II–III rectal cancer
Carterra supports AI‑designed protein study with HT-SPR platforms
Anthropic, twist and Adaptyv validate 1,320 binders across 15 targets
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
Designation supports rapid development of pan‑RAS molecular glue
Avulux gains FDA authorisation for migraine light‑sensitivity lens
New device classification created for precision optical filter
Leqembi Iqlik launches in US for early Alzheimer’s
Autoinjector offers at‑home dosing from start of treatment
Lundbeck gains EU orphan status for anti‑ACTH antibody
European ruling supports development in rare endocrine disorders
AC Immune reports positive phase 1 data for ACI‑19764
Early results show safety, CSF penetration and PK clarity
VarmX begins global phase 3 trial for VMX C001
First participant enrolled in EquilibriX S study
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
Study shows reversible switch for targeted cytokine delivery
MHRA sets out position on microbiome‑based medicinal products
Agency clarifies UK pathway for emerging therapies

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...